Adverse drug reactions: Implications for the development of fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue SUPPL. 1, 2003, Pages 21-27

  Ball, Peter ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Drug safety; Fluoroquinolones; Quinolones

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; CHLORINE DERIVATIVE; CINOXACIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; CORTICOSTEROID; FLUMEQUINE; FLUOXETINE; GAREFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; PEFLOXACIN; PIPEMIDIC ACID; PIPERAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CARDIOTOXICITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPEPSIA; FLUORINATION; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; LONG QT SYNDROME; NAUSEA; NEUROTOXICITY; PANCREATITIS; PHOTOTOXICITY; PSEUDOMONAS; REVIEW; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TENDINITIS; TORSADE DES POINTES; VERTIGO; VOMITING;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS;

EID: 0038778612     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg209     Document Type: Review

References (58)

1. Ball, P. (2000). The quinolones: history and overview. In The Quinolones, 3rd edn (Andriole, V. T., Ed.), pp. 1-31. Academic Press, London, UK.
2. Ball, P. (2000). Quinolone generations: natural history or natural selection? Journal of Antimicrobial Chemotherapy 46, Suppl. T1, 17-24.
3. Blum, M. D., Graham, D. J. & McCloskey, C. A. (1994). Temafloxacin syndrome: review of 95 cases. Clinical Infectious Diseases 18, 946-50.
4. Stahlmann, R. (2002). Clinical toxicological aspects of fluoroquinolones. Toxicology Letters 127, 269-77.
5. Ball, P., Mandell, L., Niki, Y. & Tillotson, G. (1999). Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 21, 407-21.
6. Ball, P. (2000). Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. Journal of Antimicrobial Chemotherapy 45, 557-9.
7. Chen, H. J., Bloch, K. J. & Maclean, J. A. (2000). Acute eosinophilic hepatitis from trovafloxacin. New England Journal of Medicine 342, 359-60.
8. Ball, P., Fernald, A. & Tillotson, G. (1998). Therapeutic advances of new fluoroquinolones. Expert Opinion on Investigational Drugs 7, 761-83.
9. Perry, C. M., Barman Balfour, J. A. & Lamb, H. M. (1999). Gatifloxacin. Drugs 58, 683-96; discussion 697-8.
10. Breen, J., Skuba, K. & Grasela, D. (1999). Safety and tolerability of gatifloxacin, an advanced third-generation, 8-methoxy fluoroquinolone. Journal of Respiratory Diseases 20, Suppl. 11, S70-6.
11. Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D. et al. (2002). Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrobial Agents and Chemotherapy 46, 1295-301.
12. Ball, P., File, T. M., Twynholm, M. & Henkel, T. (2001). Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. International Journal of Antimicrobial Agents 18, 19-27.
13. Hammerschlag, M. R. (2001). Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. Journal of Antimicrobial Chemotherapy 48, 735.
14. Wilson, R., Schentag, J. J., Ball, P. & Mandell, L. (2002). A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clinical Therapeutics 24, 639-52.
15. Segev, S., Yaniv, I., Haverstock, D. & Reinhart, H. (1999). Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clinical Infectious Diseases 28, 299-308.
16. Lipsky, B. A. & Baker, C. A. (1999). Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clinical Infectious Diseases 28, 352-64.
17. Tillotson, G. & Ball, P. (2002). Fluoroquinolone safety profiles - A review. Today's Therapeutic Trends 20, 419-35.
18. Davis, R. & Bryson, H. M. (1994). Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
19. Norrby, S. R., Petermann, W., Willcox, P. A., Vetter, N. & Salewski, E. (1998). A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scandinavian Journal of Infectious Diseases 30, 397-404.
20. Shah, P. M., Maesen, F. P., Dolmann, A., Vetter, N., Fiss, E. & Wesch, R. (1999). Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. Journal of Antimicrobial Chemotherapy 43, 529-39.
21. Church, D., Haverstock, D. & Andriole, V. T. (2000). Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Today's Therapeutic Trends 18, 205-23.
22. Anon. (1998). Trovafloxacin: a once daily, broad spectrum fluoroquinolone antibiotic. Formulary 33, Suppl. 3, S2-12.
23. Stahlmann, R. & Schwabe, R. (1997). Safety profile of grepafloxacin compared with other fluoroquinolones. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 83-92,
24. Domagala, J. M. (1994). Structure-activity and structure-side-effect relationships for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy 33, 685-706.
25. Jaillon, P., Morganroth, J., Brumpt, I. & Talbot, G. (1996). Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Journal of Antimicrobial Chemotherapy 37, Suppl. A, 161-7.
26. Moss, A. J. (1999). The QT interval and torsade de pointes. Drug Safety 21, Suppl. 1, 81-7.
27. Viskin, S. (1999). Long QT syndromes and torsade de pointes. Lancet 354, 1625-33.
28. Dupont, H., Timsit, J. F., Souweine, B., Gachot, B., Wolff, M. & Regnier, B. (1996). Torsades de pointe probably related to sparfloxacin. European Journal of Clinical Microbiology and Infectious Disease 15, 350-1.
29. Anderson, M. E., Mazur, A., Yang, T. & Roden, D. M. (2001). Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. Journal of Pharmacology and Experimental Therapeutics 296, 806-10.
30. Ball, P. (1999). New fluoroquinolones: real and potential roles. Current Infectious Disease Reports 1, 470-9.
31. Samaha, F. F. (1999). QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. American Journal of Medicine 107, 528-9.
32. Bertino, J. S., Jr, Owens, R. C., Jr, Carnes, T. D. & Iannini, P. B. (2002). Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clinical Infectious Diseases 34, 861-3.
33. Frothingham, R. (2002). Torsades de pointes associated with fluoroquinolones. Discussion. Pharmacotherapy 22, 668-72.
34. De Ponti, F., Poluzzi, E., Cavalli, A., Recanatini, M. & Montanaro, N. (2002). Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety 25, 263-86.
35. Oberg, K. C. & Bauman, J. L. (1995). QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 15, 687-92.
36. Darpö, B. (2001). Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. European Heart Journal 3, Suppl. K, 70-80.
37. Adverse Event Reporting System. (2002). Reports to the US FDA MedWatch Spontaneous Adverse Events reporting system 1997-2001. [Online.] http://www.fda.gov/medwatch/safety.htm (6 December 2002, date last accessed).
38. Rosen, J. E., Chen, D., Prahalad, A. K., Spratt, T. E., Schluter, G. & Williams, G. M. (1997). A fluoroquinolone antibiotic with a methoxy group at the 8 position yields reduced generation of 8-oxo-7,8-dihydro-2′-deoxyguanosine after ultraviolet-A irradiation. Toxicology and Applied Pharmacology 145, 381-7.
39. Marutani, K., Matsumoto, M., Otabe, Y., Nagamuta, M., Tanaka, K., Miyoshi, A. et al. (1993). Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrobial Agents and Chemotherapy 37, 2217-23.
40. Ball, P. (2000). Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency. International Journal of Clinical Practice 54, 329-32.
41. Man, I., Murphy, J. & Ferguson, J. (1999). Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. Journal of Antimicrobial Chemotherapy 43, Suppl. B, 77-82.
42. Ball, P. & Tillotson, G. (1995). Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Safety 13, 343-58.
43. Williams, D. & Hopkins, S. (1998). Safety of trovafloxacin in treatment of lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 17, 454-8.
44. Schacht, P., Arcieri, G., Branolte, J., Bruck, H., Chysky, V., Griffith, E. et al. (1988). Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection 16, Suppl. 1, S29-43.
45. Royer, R. J., Pierfitte, C. & Netter, P. (1994). Features of tendon disorders with fluoroquinolones. Therapie 49, 75-6.
46. Pierfitte, C. & Royer, R. J. (1996). Tendon disorders with fluoroquinolones. Therapie 51, 419-20.
47. van der Linden, P. D., Sturkenboom, M. C., Herings, R. M., Leufkens, H. G. & Stricker, B. H. (2002). Fluoroquinolones and risk of Achilles tendon disorders: case-control study. British Medical Journal 324, 1306-7.
48. Garcia Rodriguez, L. A., Stricker, B. H. & Zimmerman, H. J. (1996). Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Archives of Internal Medicine 156, 1327-32.
49. Ball, A. P. (1997). Toxicity. In Antibiotic and Chemotherapy, 7th edn (O'Grady, F., Lambert, H. P., Finch, R. G. & Greenwood, D., Eds), pp. 108-24. Churchill-Livingstone, New York, USA.
50. Nicholson, S. C., Webb, C. D. & Moellering, R. C., Jr (2002). Antimicrobial-associated acute hepatitis. Pharmacotherapy 22, 794-7.
51. Chen, D. K., McGeer, A., de Azavedo, J. C. & Low, D. E. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. New England Journal of Medicine 341, 233-9.
52. Weiss, K., Restieri, C., Gauthier, R., Laverdiere, M., McGeer, A., Davidson, R. J. et al. (2001). A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 33, 517-22.
53. Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C., Kibsey, P. et al. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747-50.
54. Kays, M. B., Smith, D. W., Wack, M. F. & Denys, G. A. (2002). Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22, 395-9.
55. Dalhoff, A. (1999). In vitro activities of quinolones. Expert Opinion on Investigational Drugs 8, 123-37.
56. Janoir, C., Zeller, V., Kitzis, M. D., Moreau, N. J. & Gutmann, L. (1996). High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrobial Agents and Chemotherapy 40, 2760-4.
57. Drlica, K. (1999). Mechanisms of fluoroquinolone action and resistance. In First International Moxifloxacin Symposium (Mandell, L., Ed.), pp. 75-83. Springer-Verlag, Berlin, Germany.
58. Urban, C., Rahman, N., Zhao, X., Mariano, N., Segal-Maurer, S., Drlica, K. et al. (2001). Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. Journal of Infectious Diseases 184, 794-8.